|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we have seen higher EGFR expression associating with worse outcomes after Photofrin-mediated PDT for MPM, and the extensive desmoplastic reaction associated with MPM influences tumor phenotype and therapeutic response.
|
30499112 |
2019 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The frequency of FOLR1 and EGFR expression in MPM was analyzed using tissue microarrays.
|
30226590 |
2018 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM.
|
30501113 |
2018 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been reported that cellular-mesenchymal to epithelial transition factor (MET) and epidermal growth factor receptor (EGFR) were critical for MPM cell proliferation.
|
28337371 |
2017 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma.
|
28870611 |
2017 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five MPM cell lines were used to test the effects of TKIs targeting EGFR (gefitinib, afatinib and lapatinib) on cell proliferation and the expression of the HER family receptor.
|
26503698 |
2015 |
|
Malignant Pleural Mesothelioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Next, the identification of less EGFR mutations in the EGFR gene of the pleural mesothelioma an up to this time unknown polymorphism in the EGFR gene was identified which could be wrongly interpreted as a mutation.
|
25679064 |
2015 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
|
23749888 |
2013 |
|
Malignant Pleural Mesothelioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.
|
23558893 |
2013 |
|
Malignant Pleural Mesothelioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53, EGFR and KRAS mutations were found in NSCLC with no link with asbestos exposure.NF2 was only altered in MPM.
|
23435014 |
2013 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
|
22449226 |
2012 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the effects of the EGFR TKIs gefitinib and erlotinib and TKIs targeted to other growth factors (VEGFR and PDGFR), in comparison to standard antineoplastic agents, in two human MPM cell lines, IST-Mes2 and ZL55.
|
21787763 |
2011 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eighty-three cases of MPM specimens were submitted to immunohistochemical (IHC) staining to evaluate the expression of EGFR protein; positive cases were submitted to fluorescence in situ hybridization (FISH) to investigate the gene status.
|
21437912 |
2011 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated 71 cases of MPM for EGFR expression in tissue.
|
20347505 |
2010 |
|
Malignant Pleural Mesothelioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
|
18383846 |
2008 |
|
Malignant Pleural Mesothelioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied EGFR gene mutation, amplification and protein expression in 25 Japanese patients with MPM.
|
18392851 |
2008 |
|
Malignant Pleural Mesothelioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Yet neither the spectrum of tissue expression nor the signalling pathways of OPN in MM and pulmonary adenocarcinoma have been characterized, although in vitro evidence links OPN to the epidermal growth factor receptor (EGFR) pathway.
|
17493236 |
2007 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study documents EGFR overexpression in MPM at the protein and the transcriptional levels; it proposes a reliable method for EGFR expression evaluation in MPM.
|
16384623 |
2006 |
|
Malignant Pleural Mesothelioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor expression of malignant pleural mesothelioma cells and primary normal cells was quantitated by means of flow cytometry.
|
15867774 |
2005 |